189 related articles for article (PubMed ID: 26207165)
1. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights.
Tampaki M; Doumba PP; Deutsch M; Koskinas J
World J Hepatol; 2015 Jul; 7(14):1834-42. PubMed ID: 26207165
[TBL] [Abstract][Full Text] [Related]
2. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
[TBL] [Abstract][Full Text] [Related]
5. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
6. Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma.
Sakon M; Monden M; Gotoh M; Kanai T; Umeshita K; Nakano Y; Mori T; Sakurai M; Wakasa K
Am J Surg; 1992 Feb; 163(2):251-6. PubMed ID: 1371207
[TBL] [Abstract][Full Text] [Related]
7. Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: a prospective cohort study.
Morimoto M; Numata K; Kondo M; Moriya S; Morita S; Maeda S; Tanaka K
Eur J Radiol; 2013 Mar; 82(3):497-503. PubMed ID: 23068563
[TBL] [Abstract][Full Text] [Related]
8. Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma.
Yuan W; Yang MJ; Xu J; Yan ZP; Liu R; Qu XD; Wang JH; Qian S
Technol Cancer Res Treat; 2018 Jan; 17():1533033818788529. PubMed ID: 30045673
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
[TBL] [Abstract][Full Text] [Related]
10. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
12. Survival outcome of salvage hepatectomy in patients with local, recurrent hepatocellular carcinoma who underwent radiofrequency ablation as their first treatment.
Ueno M; Nakai T; Hayashi M; Hirokawa F; Nagano H; Wada H; Kaibori M; Matsui K; Tanaka S; Yamaue H; Kubo S
Surgery; 2016 Sep; 160(3):661-70. PubMed ID: 27267547
[TBL] [Abstract][Full Text] [Related]
13. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
14. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
15. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein.
Nouso K; Kobayashi Y; Nakamura S; Kobayashi S; Takayama H; Toshimori J; Kuwaki K; Hagihara H; Onishi H; Miyake Y; Ikeda F; Shiraha H; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K
J Gastroenterol Hepatol; 2011 Jul; 26(7):1195-200. PubMed ID: 21410750
[TBL] [Abstract][Full Text] [Related]
18. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
Poon RT; Fan ST; Tsang FH; Wong J
Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
[TBL] [Abstract][Full Text] [Related]
19. Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment.
Cox DRA; Chung W; Grace J; Wong D; Kutaiba N; Ranatunga D; Khor R; Perini MV; Fink M; Jones R; Goodwin M; Dobrovic A; Testro A; Muralidharan V
JGH Open; 2023 Apr; 7(4):249-260. PubMed ID: 37125252
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma.
Pleguezuelo M; Germani G; Marelli L; Xiruochakis E; Misseri M; Manousou P; Arvaniti V; Burroughs AK
Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):761-84. PubMed ID: 19090737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
